ProofPilot Bolsters Advisory Board with Appointment of Michelle Everill
Michelle has over 20 years of diverse experience spanning across data analytics, clinical operations, patient recruitment and feasibility strategy. She has held leadership roles at Bristol Myers Squibb, Johnson & Johnson Innovative Medicine, Pfizer and PPD.
"Michelle adds a tremendous amount of knowledge and fresh perspectives to our team," said
As a member of the Strategic Advisory Board, Michelle will provide invaluable guidance on product direction and strategic initiatives to improve the patient, site, and study team experience in clinical trials.
"Joining ProofPilot's Strategic Advisory Board is an exciting opportunity to work with a forward-thinking team dedicated to modernizing clinical trials," said Michelle Everill, VP, Global Trial Optimization at Alnylam Pharmaceuticals, and CEO of Michelle Everill Coaching LLC. "I am eager to contribute my expertise to initiatives that will drive impactful advancements in clinical research, leveraging innovative strategies to improve trial outcomes and patient experiences."
ProofPilot will continue to announce new members of its Strategic Advisory Board, ensuring its solutions deliver immediate and long-term value for all stakeholders.
About ProofPilot
ProofPilot enhances clinical trials with its Clinical Experience Platform. The StudyCoPilot platform centralizes and simplifies communication for sponsors, patients, and sites across the clinical trial experience. Learn more at: https://www.proofpilot.com.
Media Contact: Colleen yang, [email protected]
View original content to download multimedia:https://www.prnewswire.com/news-releases/proofpilot-bolsters-advisory-board-with-appointment-of-michelle-everill-302236917.html
SOURCE ProofPilot
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Best Broadband Provider for Small Businesses UK (2026): Love Business Group Recognised for Helping SMEs Compare Business Broadband Options by Expert Consumers
- 2026 ESMO | Innovent Announcement Phase 2 Data Presentation for IBI354 (HER2 ADC) In First-line Treatment of Breast Cancer
- Binance Coin Price Holds $730 After 1.6M Burn as Buyers Bet Pepeto Can Be the Next BNB
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share